Viz.ai, a leader in AI-powered disease detection and intelligent care coordination, has announced expanded capabilities for its lung disease software. The new features incorporate natural language processing (NLP) alongside imaging AI to extract clinical insights from electronic health records (EHRs) and help identify and manage patients with lung disease. This enhancement, integrated into Viz.ai’s platform, aims to accelerate the care process, reduce time to treatment, and potentially improve outcomes for lung disease patients.
“Lung disease symptoms are often subtle and can be mistaken for other common conditions, complicating diagnosis and care decisions,” said Jack Manley, MD, head of New Markets & Growth at Viz.ai. “With over 35 million people in the U.S. suffering from lung diseases like asthma and COPD, and lung cancer remaining the top cause of cancer deaths, our AI-powered platform has the potential to speed up diagnosis, ensuring patients receive timely treatment and access to the right specialists, which can prevent life-threatening events and hospitalizations.”
Lung disease is a major health issue, being the third leading cause of death globally. Many patients with lung conditions do not receive optimal treatment due to challenges such as misidentification of high-risk patients, poor care coordination, and administrative barriers to therapy. Better care coordination can improve patient outcomes by reducing the time between diagnosis and treatment.
Viz.ai’s expanded pulmonary solutions, including its Pulmonary Embolism (PE) feature with right ventricular strain detection, will leverage NLP and imaging AI to evaluate EHR data, identify high-risk patients, and facilitate follow-up care. This expansion is part of Viz.ai’s broader mission to streamline care pathways, manage referrals, and improve patient outcomes. The company is collaborating with leading research centers and patient advocacy groups to advance these efforts. Recently, Viz.ai partnered with the Addario Lung Cancer Medical Institute (ALCMI), a global consortium of top lung cancer research institutions, to improve early detection and optimize precision medicine workflows for lung cancer patients.
